LEXINGTON, Mass., Dec. 6, 2023
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company
focused on the development of emavusertib (CA-4948), an orally
available, small molecule IRAK4 inhibitor, today announced that the
Company along with its collaborative partners will be presenting
three posters at the upcoming 65th ASH Annual Meeting and
Exposition (ASH 2025) being held in San
Diego, California and online from December 9th to December 12th.
"We are very excited to have 3 presentations at the
65th ASH annual meeting highlighting emavusertib's
continued progress in clinical studies in leukemia and lymphoma,"
said James Dentzer, President and Chief Executive Officer of
Curis.
Presentations
- TakeAim Leukemia
- Abstract Title: Preliminary Safety and Efficacy of
Emavusertib (CA-4948) in Acute Myeloid Leukemia Patients with FLT3
Mutation
- Abstract Number: 2924
- Program: Oral and Poster Abstracts
- Session: 616. Acute Myeloid Leukemias: Investigational
Therapies, Excluding Transplantation and Cellular Immunotherapies:
Poster II
- Session Date and Time: Sunday, December
10, 2023, 6:00 PM-8:00 PM
- TakeAim Lymphoma
- Abstract Title: Trial in Progress: An Open-Label
Expansion Trial Evaluating the Safety, PK/PD, and Clinical Activity
of Emavusertib (CA-4948) + Ibrutinib in R/R Primary CNS
Lymphoma
- Abstract Number: 3143
- Program: Oral and Poster Abstracts
- Session: 627. Aggressive Lymphomas: Clinical and
Epidemiological: Poster II
- Session Date and Time: Sunday, December
10, 2023, 6:00 PM-8:00 PM
- Abstract Title: Takeaim Lymphoma: An Open-Label, Dose
Escalation and Expansion Trial of Emavusertib (CA-4948) in
Combination with Ibrutinib in Patients with Relapsed or Refractory
Hematologic Malignancies
- Abstract Number: 4497
- Program: Oral and Poster Abstracts
- Session: 627. Aggressive Lymphomas: Clinical and
Epidemiological: Poster III
- Session Date and Time: Monday, December
11, 2023, 6:00 PM-8:00 PM
About emavusertib (CA-4948)
Emavusertib is an orally available, small molecule IRAK4
inhibitor. IRAK4 plays an essential role in the toll-like receptor
(TLR) and interleukin-1 receptor (IL-1R) signaling pathways, which
are frequently dysregulated in patients with cancer. TLRs and the
IL-1R family signal through the adaptor protein MYD88, which
results in the assembly and activation of IRAK4, initiating a
signaling cascade that induces cytokine and survival factor
expression mediated by the NF-κB protein complex. Preclinical
studies targeting IRAK1/4 in combination with FLT3 have
demonstrated the ability to overcome the adaptive resistance
incurred when targeting FLT3 alone. Further, emavusertib has shown
anti-tumor activity across a broad range of hematologic
malignancies including monotherapy activity in patient-derived
xenografts and synergy with both azacitidine and venetoclax.
About Curis, Inc.
Curis is a biotechnology company focused on the development of
emavusertib, an orally available, small molecule IRAK4 inhibitor.
Emavusertib is currently undergoing testing in the Phase 1/2
TakeAim Lymphoma study in patients with hematologic malignancies,
such as non-Hodgkin's lymphoma and other B cell malignancies in
combination with the BTK inhibitor ibrutinib, and as a monotherapy
in the Phase 1/2 TakeAim Leukemia study in patients with acute
myeloid leukemia and myelodysplastic syndrome, for which it has
received Orphan Drug Designation from the U.S. Food and Drug
Administration. Curis, through its 2015 collaboration with
Aurigene, has the exclusive license to emavusertib (CA-4948). Curis
licensed its rights to Erivedge® to Genentech, a member of the
Roche Group, under which they are commercializing Erivedge® for the
treatment of advanced basal cell carcinoma. For more information,
visit Curis's website at www.curis.com.
Cautionary Note Regarding Forward-Looking Statements:
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995, including, without limitation, any statements with respect
to the continued progress of emavusertib in the TakeAim
Leukemia and TakeAim Lymphoma studies including the activity,
safety and tolerability of emavusertib in such studies.
Forward-looking statements may contain the words "believes,"
"expects," "anticipates," "plans," "intends," "seeks," "estimates,"
"assumes," "predicts," "projects," "targets," "will," "may,"
"would," "could," "should," "continue," "potential," "focus,"
"strategy," "mission," or similar expressions. These
forward-looking statements are not guarantees of future performance
and involve risks, uncertainties, assumptions and other important
factors that may cause actual results to be materially different
from those indicated by such forward-looking statements. Curis may
experience adverse results, delays and/or failures in its drug
development programs and may not be able to successfully advance
the development of its drug candidates in the time frames it
projects, if at all. Curis's drug candidates may cause unexpected
toxicities, fail to demonstrate sufficient safety and efficacy in
clinical studies and/or may never achieve the requisite regulatory
approvals needed for commercialization. Favorable results seen in
preclinical studies and early clinical trials of Curis's drug
candidates may not be replicated in later trials. There can be no
guarantee that the collaboration agreement with Aurigene will
continue for its full term, or the CRADA with NCI, that Curis or
its collaborators will each maintain the financial and other
resources necessary to continue financing its portion of the
research, development and commercialization costs, or that the
parties will successfully discover, develop or commercialize drug
candidates under the collaboration. Regulatory authorities may
determine to delay or restrict Genentech's and/or Roche's ability
to continue to commercialize Erivedge in basal cell carcinoma.
Competing drugs may be developed that are superior to Erivedge. In
connection with its agreement with Oberland Capital, Curis faces
risks relating to the transfer and encumbrance of certain royalty
and royalty-related payments on commercial sales of Erivedge,
including the risk that, in the event of a default by Curis or its
wholly-owned subsidiary, Curis could lose all retained rights to
future royalty and royalty-related payments, Curis could be
required to repurchase such future royalty and royalty-related
payments at a price that is a multiple of the payments it has
received, and its ability to enter into future arrangements may be
inhibited, all of which could have a material adverse effect on its
business, financial condition and stock price. Curis will require
substantial additional capital to fund its business. If it is not
able to obtain sufficient funding, it will be forced to delay,
reduce in scope or eliminate some of its research and development
programs, including related clinical trials and operating expenses,
potentially delaying the time to market for, or preventing the
marketing of, any of its product candidates, which could adversely
affect its business prospects and its ability to continue
operations, and would have a negative impact on its financial
condition and its ability to pursue its business strategies. Curis
faces substantial competition. Curis and its collaborators face the
risk of potential adverse decisions made by the FDA and other
regulatory authorities, investigational review boards, and
publication review bodies. Curis may not obtain or maintain
necessary patent protection and could become involved in expensive
and time-consuming patent litigation and interference proceedings.
Unstable market and economic conditions, natural disasters, public
health crises, political crises and other events outside of Curis's
control could significantly disrupt its operations or the
operations of third parties on which Curis depends and could
adversely impact Curis's operating results and its ability to raise
capital. Other important factors that may cause or contribute
to actual results being materially different from those indicated
by forward-looking statements include the factors set forth under
the captions "Risk Factor Summary" and "Risk Factors" in our most
recent Form 10-K and Form 10-Q, and the factors that are discussed
in other filings that we periodically make with the Securities and
Exchange Commission. In addition, any forward-looking statements
represent the views of Curis only as of today and should not be
relied upon as representing Curis's views as of any subsequent
date. Curis disclaims any intention or obligation to update any of
the forward-looking statements after the date of this press release
whether as a result of new information, future events or otherwise,
except as may be required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/curis-announces-three-presentations-at-ash-302006952.html
SOURCE Curis, Inc.